首页> 外文期刊>ESC Heart Failure >The association between high‐dose loop diuretic use at discharge and cardiovascular mortality in patients with heart failure
【24h】

The association between high‐dose loop diuretic use at discharge and cardiovascular mortality in patients with heart failure

机译:心力衰竭患者出院时大剂量loop利尿剂使用与心血管死亡率之间的关系

获取原文
           

摘要

Aims Few studies have reported the impact of high‐dose loop diuretics at discharge on prognosis in Japanese patients with heart failure (HF). Our purpose was to assess the relationship between the dose of loop diuretics at discharge and cardiovascular mortality in patients with HF. Methods and results We enrolled decompensated HF patients who were admitted to our hospital between March 2010 and March 2015, and compared HF patients who received high‐dose loop diuretics at discharge (HD group) with low‐dose loop diuretics at discharge (LD group) with regard to risk of cardiovascular mortality, and all‐cause mortality. High‐dose loop diuretic was defined as ≥40?mg/day of oral furosemide at discharge. A total of 215 patients were enrolled to the study. The median follow‐up duration was 641?days. All‐cause and cardiovascular mortality were significantly lower in the LD group than in the HD group (10.4% vs. 31.6%, P ??0.001; 2.2% vs. 24.6%, P ??0.001, respectively). High‐dose loop diuretics were associated with cardiovascular mortality in multivariate Cox proportional hazards model (hazard ratio, 16.06, 95% confidence interval 3.457 to 116.8; P ??0.001). The largest area under the receiver operating characteristic curve (0.85) for cardiovascular death was obtained with a threshold of 40?mg furosemide. Conclusions High‐dose loop diuretic use at discharge was one of the predictors of cardiovascular mortality in patients with HF. An oral furosemide dose of 40?mg daily may be defined as ‘high‐dose’ loop diuretics in Japanese patients with chronic HF.
机译:目的很少有研究报道出院时大剂量loop利尿剂对日本心力衰竭(HF)患者的预后影响。我们的目的是评估HF患者出院时of利尿剂的剂量与心血管死亡率之间的关系。方法和结果我们纳入了2010年3月至2015年3月在我院住院的失代偿性HF患者,并对出院时使用大剂量high利尿剂的HD患者(HD组)与出院时使用小剂量low利尿剂的患者(LD组)进行了比较。关于心血管疾病的死亡率和全因死亡率。大剂量loop利尿剂定义为出院时口服呋塞米≥40?mg /天。共有215名患者参加了研究。中位随访时间为641天。 LD组的全因和心血管死亡率均显着低于HD组(分别为10.4%vs. 31.6%,P <0.001); 2.2%vs.24.6%,P <0.001)。在多变量Cox比例风险模型中,大剂量loop利尿剂与心血管疾病死亡率相关(风险比为16.06,95%置信区间为3.457至116.8; P <0.001)。接受者的工作特征曲线下最大面积(0.85)导致了心血管死亡,阈值为40?mg速尿。结论出院时大剂量loop利尿剂使用是心衰患者心血管死亡率的预测指标之一。在日本慢性HF患者中,每天口服呋塞米40?mg可能被定义为“大剂量” di利尿剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号